SEC Form 4 · accession 0001209191-18-003127
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eiry Roberts
Officer — Chief Medical Officer
Period of report
Jan 8, 2018
Accepted (ET)
Jan 10, 2018 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF1 | $77.81 | Jan 8, 2018 | A | 70,000 | A | — | Jan 8, 2028 | Common Stock | 70,000 | 70,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 8, 2018 | A | 20,000 | A | — | — | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F2Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F3The Restricted Stock Units will vest annually at 25% of the units vesting on each of January 8, 2019, January 8, 2020, January 8, 2021, and January 8, 2022.